Kiora Pharmaceuticals (NASDAQ: KPRX) announced today that its novel ion channel modulator, KIO-300, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.
The data demonstrated a significant reduction in epileptiform activity, a hallmark of seizure generation. KIO-300 is the active pharmaceutical ingredient of KIO-301, which is currently in a Phase 2 clinical program for vision restoration in patients with retinitis pigmentosa, a genetic eye disease. This new preclinical evidence suggests that the ion channel modulator platform may have therapeutic potential beyond ophthalmology, specifically in neurological disorders such as epilepsy.
Kiora's ion channel modulator platform targets critical pathways underlying diseases by modulating ion channel activity. The company's lead candidate, KIO-301, is a molecular photoswitch that aims to restore vision in patients with inherited or age-related retinal degeneration. The positive results in an epilepsy model indicate that the platform could be leveraged for additional indications, potentially expanding the company's pipeline.
For more details, the full announcement is available here. Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease, with programs in retinitis pigmentosa, choroideremia, Stargardt disease, and macular edema. The company's forward-looking statements involve risks and uncertainties, including the ability to conduct clinical trials and obtain regulatory approvals.
